New policies on the use of corticosteroids and bronchodilators-including Clenbuterol–for all yearlings, horses in and out of training and unraced 2-year-olds will be introduced at the beginning of the UK and Irish yearling sales from Sept. 1 forward, Tattersalls and Goffs announced on Monday. Starting with the Goffs UK Premier Yearling Sale, all stock sold at the two sales companies will have these restrictions applied. These new Conditions of Sale will allow buyers to have post-sale testing for corticosteroids and bronchodilators (Clenbuterol). Any positive test or any trace of bronchodilators that appear as a result of the testing may result in the subject horse being returnable to the vendor at the option of the purchaser under the new Conditions of Sale.
These new regulations are in addition to the restrictions already in place on the use of anabolic steroids and non-steroidal anti-inflammatories, as well as the ban on the utilisation of Bisphosphonates which started in 2019.
“Both Tattersalls and Goffs are united in maintaining the highest standards of integrity and horse welfare at all of our sales and the new policies relating to the use of corticosteroids and bronchodilators reflect our shared commitment to addressing issues which threaten in any way to undermine confidence in the marketplace,” said Tattersalls Chairman Edmond Mahony and Goffs Group Chief Executive Henry Beeby in a joint statement.
Not a subscriber? Click here to sign up for the daily PDF or alerts.
